Back
Non classé
1 min read

[Press Release] Effectiveness of XAV19 against SARS-CoV-2 variants

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 7 avril 2021

Related Posts

XENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody

June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone

Read More

XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France

June, 2024. During its participation in ASCO, XENOTHERA….

Read More

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

November 27, 2023. # Download our press release (english version) # Télécharger...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in